Objectives: To compare the proportion of interval left-sided colorectal cancers (CRCs) after flexible sigmoidoscopy vs colonoscopy in older patients and to identify factors associated with interval CRC.

Patients And Methods: Using the Surveillance, Epidemiology, and End Results-Medicare-linked database, we studied patients 67 years or older with left-sided CRC who had at least one lower endoscopy performed within the previous 36 months between July 1, 2001, and December 31, 2005. The CRCs diagnosed within 6 months of lower endoscopy were defined as detected CRCs; CRCs diagnosed 6 to 36 months after lower endoscopy were defined as interval CRCs. The proportion of interval CRCs was calculated as number of interval CRCs divided by number of detected and interval CRCs. The χ(2) test and a multivariate logistic regression model were used in the statistical analysis.

Results: Of 15,484 older patients with left-sided CRC, the proportion of interval CRCs after flexible sigmoidoscopy was 8.8% compared with 2.5% after colonoscopy (P<.001). This difference was similar across left colon locations and largest in the descending colon (17.1% vs 3.5%; P<.001). In multivariate logistic regression, the odds of interval CRC after flexible sigmoidoscopy was 3 times as high as that after colonoscopy (odds ratio, 3.52; 95% CI, 2.66-4.65).

Conclusion: In older patients with left-sided CRC, the odds of interval CRC after flexible sigmoidoscopy was 3 times as high as that after colonoscopy. Whether this finding reflects differences in bowel preparation quality, sedation use, or depth of insertion warrants future research.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mayocp.2013.02.010DOI Listing

Publication Analysis

Top Keywords

interval crcs
20
flexible sigmoidoscopy
12
older patients
12
proportion interval
12
lower endoscopy
12
crcs
9
interval
8
interval left-sided
8
left-sided colorectal
8
colonoscopy older
8

Similar Publications

Objectives: In two large university affiliated healthcare systems, we examined trends in colorectal cancer (CRC) screening both prior to and during the COVID-19 pandemic to compare the trends in non-invasive screening tests and colonoscopy.

Materials And Methods: In this retrospective time-trend analysis, we obtained the numbers of colonoscopies and non-invasive tests performed monthly during the pandemic and the year prior to it. We obtained colonoscopy data from five endoscopy units with the indication determined by dual independent review.

View Article and Find Full Text PDF

Background: Iron deficiency anaemia (IDA) related to occult gastrointestinal tract (GIT) blood loss is associated with high rates of GIT malignancies. Major society guidelines recommend bidirectional endoscopic evaluation for all men and post-menopausal women with newly diagnosed, unexplained IDA. However, in patients prescribed direct oral anticoagulants (DOACs), the endoscopic yield, specifically the rate of high-risk findings, including colorectal cancers (CRCs) and advanced adenomas (AAs), is unknown.

View Article and Find Full Text PDF

Upper age limits are currently fixed for all fecal immunochemical test (FIT)-based colorectal cancer (CRC) screening programs. A risk-stratified upper age limit may be beneficial. Therefore, we assessed differences in interval CRC risk among individuals who had reached the upper age limit of screening (75 years).

View Article and Find Full Text PDF
Article Synopsis
  • - The study explores the combination of pembrolizumab (an anti-PD1 therapy) and trebananib (an angiopoietin inhibitor) in patients with metastatic ovarian cancer and microsatellite stable (MSS) colorectal cancer, as both cancers show resistance to PD1 immunotherapy.
  • - Results indicate that the highest tolerated dose of the combination therapy is trebananib at 30 mg/kg weekly plus pembrolizumab at 200 mg every 3 weeks, with a modest overall response rate of 7.3%, including durable responses in three MSS CRC patients.
  • - The successful patients exhibited particular tumor characteristics, such as left-sided CRC and no liver metastases; highlighting the need for further research into how
View Article and Find Full Text PDF

Background And Aims: Patients with screen-detected colorectal cancer (CRC) have a better stage-specific overall survival than non-screen-detected CRC. Currently, it is unknown if recurrence rates differ between screen-detected and non-screen-detected CRCs, and whether this could explain the observed difference in overall survival. Therefore, we aimed to assess the disease-free survival (DFS) rates in screen-detected and non-screen-detected CRCs and if recurrence affects overall survival.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!